| Literature DB >> 18092143 |
Shinji Urakami1, Hiroaki Shiina, Masahiro Sumura, Satoshi Honda, Koji Wake, Takeo Hiraoka, Shogo Inoue, Noriyoshi Ishikawa, Mikio Igawa.
Abstract
Metastatic prostate cancer (PC) is incurable by androgen deprivation therapy alone, due to the presence of androgen-independent/supersensitive cells in hormone-naive PC. A 67-year-old man was diagnosed with PC (Gleason score, 5 + 4) with multiple bone metastases. He was treated by chemohormonal therapy with cisplatin and estramustine phosphate (EMP) followed by maximal androgen blockade, and showed a complete response. As of the time of writing, no clinical or prostate-specific antigen recurrence has been observed for over 15 years, despite cessation of the treatment. This is the first report to indicate a possible cure of metastatic PC by chemohormonal therapy combined with appropriate anti-tumor drugs targeted to both androgen-independent and -dependent clones before the hormone-refractory state.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18092143 DOI: 10.1007/s11255-007-9301-z
Source DB: PubMed Journal: Int Urol Nephrol ISSN: 0301-1623 Impact factor: 2.370